VYNE Therapeutics Inc.VYNENASDAQ
Loading
Revenue Growth Under PressureDecelerating
Percentile Rank32
Year-over-Year Change
Year-over-year revenue growth rate
Percentile
P32
Within normal range
vs 5Y Ago
-0.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -23.08% |
| Q3 2025 | 144.93% |
| Q2 2025 | -65.84% |
| Q1 2025 | 140.48% |
| Q4 2024 | -30.58% |
| Q3 2024 | -38.89% |
| Q2 2024 | 102.04% |
| Q1 2024 | 28.95% |
| Q4 2023 | -33.33% |
| Q3 2023 | -15.56% |
| Q2 2023 | 36.36% |
| Q1 2023 | 1550.00% |
| Q4 2022 | -96.41% |
| Q3 2022 | 32.54% |
| Q2 2022 | -29.21% |
| Q1 2022 | -92.23% |
| Q4 2021 | 1623.31% |
| Q3 2021 | -54.92% |
| Q2 2021 | 28.26% |
| Q1 2021 | -94.63% |
| Q4 2020 | 31.11% |
| Q3 2020 | -72.03% |
| Q2 2020 | 567.89% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |
| Q3 2019 | 0.00% |
| Q2 2019 | 0.00% |
| Q1 2019 | 100.00% |
| Q4 2018 | 0.00% |
| Q3 2018 | -100.00% |
| Q2 2018 | 1940.85% |
| Q1 2018 | -82.09% |
| Q4 2017 | 205.28% |
| Q3 2017 | 102.45% |
| Q2 2017 | 0.00% |
| Q1 2017 | -0.22% |
| Q4 2016 | 100.89% |
| Q3 2016 | 0.00% |